Mining Sector Ideas

[gfp927z]

Bigworld, Here's the recent Acurx conference call transcript (next post). Apparently there isn't an audio replay available, but only the transcript. These almost always have some mistakes, misspellings, but at least we can get the gist of it.

A big omission is that they didn't mention the 94 day extended durability data, which was previously reported in a Jan 29 press release (link below). The problem is that only 5 patients (out of 15) had agreed to be monitored for the full 94 days (!). All 5 had no recurrence, so that's good, but what about the other 10?? If even one of them experienced C Dif recurrence, that could be massive, especially since the Vanc arm surprisingly had no recurrence either (though only 7 out of 14 Vanc patients had agreed to be followed for 94 days).

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173728795

Anyway, I figure this piddly amount of 94 day data may not be enough to get an acceptable partnering offer from a big pharma, in which case Acurx will have to do the first Phase 3 inhouse, raise the money, etc, yikes. When that Jan 29 press release came out, I decided to not get back into the stock, and just watch from the sidelines.

A deal later this year is not impossible, but the odds have dropped without that 94 day data. The trend had been looking good from the 30 day data, with 2 or the 14 Vanc patients having recurrence, vrs none of the 15 Ibeza patients with recurrence. But that trend needed to be confirmed by the 94 day data. In the Phase 2b, Ibeza already had one patient who failed to respond to treatment (vrs a perfect 100% for Vanc), which tanked the stock back in Oct. Anyway, bottom line there's no substitute for a larger trial to determine what Ibeza can really do. A lot of promise, but we really need to see the data from a few hundred patients, and potential pharma partners may come to that same conclusion. So.. the prospect of more dilution and the ATM piranha for several years, ugh. That's what has tanked the stock.



---